Venus Concept Inc.
VERODrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How VERO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CSE-1034 (Ceftriaxone + Sulbactam + EDTA) | Phase 3 | Urinary Tract Infection Complicated | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Venus Concept Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Venus Concept Inc.'s (VERO) pipeline across Phase 3. Its lead program is CSE-1034 (Ceftriaxone + Sulbactam + EDTA) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Venus Concept Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Venus Concept Inc. (VERO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VERO biotech catalysts?→
Add VERO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Venus Concept Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.